2020
Risk Profiling of Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients By Measuring Circulating Tumor DNA
Herrera A, Tracy S, Croft B, Opat S, Ray J, Musick L, Paulson J, Sehn L, Jiang Y. Risk Profiling of Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients By Measuring Circulating Tumor DNA. Blood 2020, 136: 23-25. DOI: 10.1182/blood-2020-136645.Peer-Reviewed Original ResearchProgression-free survivalCirculating tumor DNACurrent equity holderInternational Prognostic IndexEntity's Board of DirectorsDetect circulating tumor DNABaseline ctDNA levelCtDNA levelsOverall survivalR/R DLBCLHazard ratioPrognostic factorsHigh riskTumor DNARefractory diffuse large B-cell lymphomaDiffuse large B-cell lymphoma patientsDiffuse large B-cell lymphomaMeasuring circulating tumor DNASource of germline DNACirculating tumor DNA levelsB-cell lymphoma patientsLarge B-cell lymphomaLactate dehydrogenaseEarly identification of patientsFirst-line setting
2019
S845 PREDICTED NEOANTIGENS PROVIDE PROGNOSTIC INSIGHT IN DLBCL
Paulson J, Jin D, Sokol E, Nielsen T, Venstrom J, Trabucco S. S845 PREDICTED NEOANTIGENS PROVIDE PROGNOSTIC INSIGHT IN DLBCL. HemaSphere 2019, 3: 377. DOI: 10.1097/01.hs9.0000561660.80605.a5.Peer-Reviewed Original ResearchDiffuse large B-cell lymphomaTumor mutational burdenComprehensive genomic profilingNeoantigen burdenImmune surveillanceClinical outcomesPrognostic insightsPoor outcomeEstimate tumor mutation burdenMedian tumor mutation burdenPersonalized cancer vaccine strategiesHigh tumor mutational burdenLarge B-cell lymphomaEvasion of immune surveillanceVaccination strategiesCancer vaccine strategiesAssociated with worsened outcomesB-cell lymphomaMultivariate Cox regressionImpact clinical outcomesCell of originMHC-I presentationBCL2 alterationsDLBCL cohortPrognostic factors